Eccenovo

Eccenovo is a clinical-stage biotechnology company dedicated to the discovery and development of transformative medicines for patients with rare diseases and high unmet medical needs. The company's primary focus is on lysosomal storage disorders and neurodegenerative conditions, leveraging its expertise in small molecule drug discovery. Its lead candidate, ECN-001, is an orally bioavailable small molecule currently in clinical development for the treatment of Niemann-Pick disease type C (NPC). Eccenovo aims to address the underlying pathophysiology of these complex diseases to provide meaningful clinical benefits. Headquartered in Beijing with operations in the United States, the company is supported by a network of prominent healthcare investors.